We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

108 hedge funds and large institutions have $194M invested in Sutro Biopharma in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 43 increasing their positions, 32 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 32

0.28% more ownership

Funds ownership: 8.95% → 9.23% (+0.28%)

10% less funds holding

Funds holding: 120 → 108 (-12)

23% less capital invested

Capital invested by funds: $252M → $194M (-$57.3M)

25% less call options, than puts

Call options by funds: $3K | Put options by funds: $4K

61% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 18

Holders
108
Holders Change
-12
Holders Change %
-10%
% of All Funds
1.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
43
Reduced
32
Closed
18
Calls
$3K
Puts
$4K
Net Calls
-$1K
Net Calls Change
-$23K

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$12.5M
2
Verition Fund Management
Verition Fund Management
Connecticut
+$2.42M
3
UOC
UBS O'Connor
Illinois
+$1.44M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.41M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$520K

Top Sellers

1
RCMNY
Rubric Capital Management (New York)
New York
-$3.07M
2
OM
Opaleye Management
Massachusetts
-$1.43M
3
Millennium Management
Millennium Management
New York
-$1.15M
4
Man Group
Man Group
United Kingdom
-$1.08M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$995K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$20.8M -$82.6K -1,896 -0.3%
SCM
2
Suvretta Capital Management
New York
$20.4M – – –
BI
3
BVF Inc
California
$11.6M – – –
RCMNY
4
Rubric Capital Management (New York)
New York
$11.6M -$3.07M -70,393 -17%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$10.8M +$12.5M +287,941 +1,276%
Vanguard Group
6
Vanguard Group
Pennsylvania
$9.95M +$169K +3,885 +1%
Franklin Resources
7
Franklin Resources
California
$9.84M -$145K -3,318 -1%
Verition Fund Management
8
Verition Fund Management
Connecticut
$8.68M +$2.42M +55,502 +29%
Holocene Advisors
9
Holocene Advisors
New York
$7.4M – – –
Baillie Gifford & Co
10
Baillie Gifford & Co
United Kingdom
$6.48M – – –
SB
11
Samsara BioCapital
California
$5.81M – – –
KCM
12
Kynam Capital Management
New Jersey
$5.39M +$230K +5,268 +4%
CS
13
Candriam SCA
Luxembourg
$5.34M -$392K -9,000 -6%
Millennium Management
14
Millennium Management
New York
$4.3M -$1.15M -26,434 -18%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$4.15M +$155K +3,562 +3%
PHP
16
Parkman Healthcare Partners
Connecticut
$4.1M +$167K +3,831 +3%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$3.92M -$357K -8,197 -7%
State Street
18
State Street
Massachusetts
$3.84M +$50.8K +1,167 +1%
Goldman Sachs
19
Goldman Sachs
New York
$3.79M -$32.6K -748 -0.7%
FLSM
20
Frazier Life Sciences Management
California
$2.71M – – –
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$2.68M +$520K +11,940 +18%
EP
22
Eversept Partners
New York
$2.67M +$94.7K +2,173 +3%
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$1.85M +$1.41M +32,415 +155%
Northern Trust
24
Northern Trust
Illinois
$1.69M +$12K +275 +0.6%
Vontobel Holding
25
Vontobel Holding
Switzerland
$1.56M +$151K +3,469 +8%
1
2 3 4 5

STRO Hedge Fund Activity: Q3 2023 in Review

108 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2023, worth a combined $194M — down 23% from $252M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of STRO and 7 opened new positions — a net loss of 11 holders — while 32 trimmed existing stakes and 43 added.

The largest buyer was Adage Capital Partners, adding an estimated $12.5M. The largest seller was Rubric Capital Management (New York), cutting an estimated $3.07M.

  • 108 institutional investors held Sutro Biopharma (STRO) as of Q3 2023, down from 120 in Q2 2023.
  • Funds reported $194M of Sutro Biopharma stock for Q3 2023, down 23% quarter-over-quarter.
  • 7 funds opened new Sutro Biopharma positions in Q3 2023 and 18 closed out, a net change of -11 holders.
  • The largest Sutro Biopharma buyer in Q3 2023 was Adage Capital Partners, an estimated $12.5M added.
  • The largest Sutro Biopharma seller in Q3 2023 was Rubric Capital Management (New York), an estimated $3.07M sold.

Based on aggregated 13F filings for Q3 2023.